Press release
Artificial Intelligence (AI) in Cancer Diagnostics Market Poised for Robust Growth, Reaching USD 2.43 Billion by 2032 | DelveInsight
Artificial Intelligence (AI) in Cancer Diagnostics Market
DelveInsight's latest report, "Artificial Intelligence (AI) in Cancer Diagnostics Market 2032" by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-User (Hospitals, Diagnostic Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)," forecasts steady market growth at a CAGR of 11.16% from 2025 to 2032.
Request for sample report @ Artificial Intelligence (AI) in Cancer Diagnostics Market Size Analysis [https://www.delveinsight.com/sample-request/artificial-intelligence-ai-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Artificial Intelligence (AI) in Cancer Diagnostics Market Summary
The global Artificial Intelligence (AI) in Cancer Diagnostics Market was valued at USD 1,049.18 million in 2024 and is projected to reach USD 2,434.32 million by 2032, growing at a CAGR of 11.16% during the forecast period (2025-2032). The growing burden of cancer worldwide, coupled with the increasing need for accurate, fast, and cost-effective diagnostic tools, is driving the adoption of AI-powered solutions in oncology.
With cancer being one of the leading causes of mortality globally, healthcare systems are prioritizing early detection and precision diagnostics. AI, integrated with medical imaging modalities such as CT scans, MRIs, mammograms, and pathology slides, has emerged as a transformative tool in cancer diagnostics. These technologies improve diagnostic accuracy, minimize human error, and enable earlier disease detection-factors that are critical in improving survival rates and treatment outcomes.
Furthermore, major players in the healthcare and technology sectors are increasingly focusing on strategic collaborations, product launches, and acquisitions to strengthen their AI-based cancer diagnostics portfolios. These developments are expected to significantly expand the global reach and technological capabilities of AI in the cancer diagnostics landscape.
To read more about the latest highlights related to the AI in cancer diagnostics market, get a snapshot of the key highlights entailed in the Global AI in Cancer Diagnostics Market Report [https://www.delveinsight.com/sample-request/artificial-intelligence-ai-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Artificial Intelligence (AI) in Cancer Diagnostics Market Dynamics
According to the International Agency for Research on Cancer (IARC, 2024), an estimated 20 million new cancer cases were reported globally in 2022, with projections indicating a rise to 32.6 million cases by 2045. Among these, breast cancer alone accounted for around 2.3 million new cases in 2022, expected to reach 3.36 million by 2045. Such alarming growth in cancer prevalence underscores the urgent need for enhanced diagnostic technologies.
AI is increasingly being recognized as an indispensable component of cancer care, particularly in early and accurate detection. Traditional methods-such as manual image interpretation and tissue biopsies-are often limited by subjectivity, time constraints, and diagnostic variability. In contrast, AI-powered systems leverage deep learning and machine learning algorithms to analyze massive datasets from imaging and molecular diagnostics, delivering rapid and precise results.
AI models are capable of detecting complex patterns invisible to the human eye, significantly reducing diagnostic errors. They can differentiate between benign and malignant tumors with high specificity, minimize false positives, and reduce unnecessary biopsies. Moreover, AI integration in diagnostic workflows allows for real-time decision support, disease monitoring, and prediction of treatment response.
Transformative Impact of AI on Cancer Imaging and Pathology
The integration of AI into medical imaging has redefined the accuracy and efficiency of cancer diagnostics. AI-driven imaging platforms, equipped with deep learning-based computer vision technologies, are capable of automating tasks such as lesion detection, segmentation, and tumor classification. This not only reduces the burden on pathologists and radiologists but also enhances the reproducibility and standardization of diagnostic results.
Advanced AI models are now able to evaluate multi-parametric imaging data to detect early-stage tumors and subtle abnormalities. For instance, AI systems used in mammography screening have demonstrated remarkable accuracy in identifying microcalcifications indicative of early breast cancer. Similarly, AI-enabled lung cancer screening tools can detect nodules with higher sensitivity than traditional imaging review methods.
AI also plays a pivotal role in digital pathology. Automated histopathological slide analysis powered by neural networks provides precise tissue segmentation and cancer grading. Additionally, AI's capability to integrate genomic, radiomic, and clinical data supports oncologists in developing personalized treatment plans based on patient-specific molecular signatures.
A key example of this innovation came in September 2024, when Roche expanded its digital pathology platform by integrating over 20 advanced AI algorithms from eight partners into its navify Registered Digital Pathology enterprise software. This integration offers pathologists direct access to AI-powered image analysis, enhancing diagnostic consistency and accelerating research in oncology.
Artificial Intelligence (AI) in Cancer Diagnostics Challenges and Restraints
Despite the remarkable potential of AI in oncology, the market faces challenges such as limited data availability, model bias, and regulatory complexities. AI systems require vast, high-quality, and diverse datasets for effective training and validation. However, data fragmentation, privacy concerns, and inconsistencies in clinical information often hinder this process.
Additionally, the lack of standardized validation frameworks and the stringent regulatory approval processes for AI-based medical devices can delay market entry. Ethical issues surrounding data usage and the "black box" nature of AI decision-making remain key areas of concern for regulatory authorities and clinicians alike.
Nonetheless, the industry continues to make strides in addressing these limitations through global collaborations, standardized protocols, and transparent algorithmic design.
Get a sneak peek at the AI in cancer diagnostics market dynamics @ AI in Cancer Diagnostics Market Dynamics Analysis [https://www.delveinsight.com/sample-request/artificial-intelligence-ai-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Artificial Intelligence (AI) in Cancer Diagnostics Market Segment Insights
Artificial Intelligence (AI) in Cancer Diagnostics Market By Component: Software and Services
In 2024, the software segment dominated the market and is projected to continue leading throughout the forecast period. AI-powered software solutions are at the forefront of cancer diagnostics, enabling precise image interpretation, workflow automation, and predictive analytics.
Through deep learning and machine learning algorithms, these platforms can efficiently process high-resolution medical images from CT, MRI, PET, and digital pathology, providing early detection and accurate disease classification. The use of cloud-based AI solutions further allows real-time data sharing, remote collaboration, and integration with Electronic Health Records (EHRs), improving overall efficiency in clinical decision-making.
For example, in October 2024, Owkin, an AI-biotech company, launched MSIntuit Registered CRC v2, a next-generation AI software designed to enhance colorectal cancer (CRC) detection and treatment. Integrated into Roche's navify Registered platform, this solution exemplifies how AI software is reshaping clinical workflows by offering precision insights into tumor microenvironments and mutation profiles.
As regulatory approvals increase and clinical adoption accelerates, the software segment is expected to contribute substantially to market expansion between 2025 and 2032.
Artificial Intelligence (AI) in Cancer Diagnostics Market By Cancer Type
Among cancer types, breast cancer is projected to hold the largest market share due to its high global incidence and the widespread use of imaging-based screening programs. AI-enabled mammography interpretation systems are improving early detection rates and reducing false-negative results, which is vital for effective patient management.
AI also shows significant promise in lung cancer and colorectal cancer diagnostics. AI-assisted CT and colonoscopy interpretation tools can identify nodules or polyps with superior accuracy, supporting timely interventions. Meanwhile, AI integration in prostate and brain cancer diagnostics enhances tumor visualization and treatment planning through multimodal image fusion and predictive modeling.
Artificial Intelligence (AI) in Cancer Diagnostics Market By End User
The hospital segment remains the leading end-user of AI in cancer diagnostics due to its access to advanced imaging infrastructure and high patient throughput. Hospitals are increasingly adopting AI-driven radiology and pathology software to streamline operations, improve diagnostic consistency, and reduce turnaround times.
Diagnostic centers and specialized imaging facilities are also witnessing rapid adoption of AI tools for high-volume image analysis and second-opinion services, particularly in developed regions. These centers benefit from the scalability and interoperability of AI software, which facilitates cross-institutional collaboration and centralized data analysis.
To know more about why North America is leading the market growth in the AI in cancer diagnostics market, get a snapshot of the AI in Cancer Diagnostics Market Outlook [https://www.delveinsight.com/sample-request/artificial-intelligence-ai-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Artificial Intelligence (AI) in Cancer Diagnostics Market By Geography
North America Artificial Intelligence (AI) in Cancer Diagnostics Market: The Market Leader
North America accounted for the largest share of the global AI in cancer diagnostics market in 2024 and is expected to maintain its dominance through 2032. The region's leadership is supported by high cancer prevalence, advanced healthcare infrastructure, government funding for AI research, and the presence of leading AI developers and medical imaging companies.
According to IARC (2024), North America reported approximately 2.67 million new cancer cases in 2022, projected to increase to 3.83 million by 2045. Breast cancer alone contributed to more than 300,000 cases in 2022. AI-assisted imaging systems are proving crucial in this region, enhancing breast and prostate cancer screening accuracy and minimizing diagnostic disparities.
Strategic collaborations and technological innovations further strengthen the market. In October 2023, Philips collaborated with Quibim, a pioneer in imaging biomarkers, to launch AI-powered MRI prostate screening tools, advancing precision diagnostics in urology and oncology.
Europe and Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market: Emerging Growth Hotspots
Europe represents a major growth region, driven by strong regulatory support for digital health technologies and rising adoption of AI in national cancer programs. Meanwhile, Asia-Pacific is expected to witness the fastest growth rate due to increasing healthcare investments, large patient populations, and expanding access to diagnostic technologies in emerging economies such as India and China.
Recent Developments in Artificial Intelligence (AI) in Cancer Diagnostics Market
* August 2025: Esaote received FDA approval for its MyLab Trademark A50 and A70 ultrasound systems, enabling enhanced diagnostic imaging performance in U.S. markets.
* August 2025: The FDA granted De Novo authorization to ArteraAI Prostate, the first AI-powered Software as a Medical Device (SaMD) for predicting long-term outcomes in non-metastatic prostate cancer.
* August 2023: MVision AI launched version 1.2.4 of its automatic segmentation software, improving accuracy in cancer radiotherapy planning.
* January 2023: Paige AI Inc. announced a partnership with Microsoft to develop next-generation clinical applications for digital pathology, integrating AI-driven computational biomarkers for improved cancer diagnosis.
Artificial Intelligence (AI) in Cancer Diagnostics Market Competitive Landscape
The market features several leading companies focusing on product innovation, strategic partnerships, and acquisitions to strengthen their foothold. Prominent players include:
iCAD, Inc. | Ibex-ai | Roche Diagnostics | Kheiron Medical Technologies Limited | MVision AI Inc. | Siemens Healthineers AG | GE HealthCare | NVIDIA Corporation | Digital Diagnostics Inc. | IBM Corporation | Azra AI | ConcertAI | PathAI | Median Technologies | Paige AI Inc. | Therapixel | Flatiron | Freenome Holdings Inc. | Onc.AI | Sonrai Analytics
These companies are leveraging advancements in machine learning, natural language processing, and cloud computing to develop scalable AI-based diagnostic platforms capable of integrating with existing healthcare systems.
Which MedTech key players in the AI in cancer diagnostics market are set to emerge as the trendsetter explore @ AI in Cancer Diagnostics Companies [https://www.delveinsight.com/sample-request/artificial-intelligence-ai-in-cancer-diagnostics-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Artificial Intelligence (AI) in Cancer Diagnostics Market Report
* Market Size (2024): USD 1,049.18 million
* Forecast (2032): USD 2,434.32 million
* CAGR (2025-2032): 11.16%
* Key Drivers: Rising cancer incidence, AI integration in imaging, growing digital health infrastructure
* Top Segments: Software and Breast Cancer Diagnostics
* Dominant Region: North America
* Key Trends: Strategic collaborations, FDA approvals, and adoption of cloud-based AI platforms
Analysts Commentary
The Artificial Intelligence in Cancer Diagnostics Market is entering a transformative era, driven by technological innovation, growing disease burden, and increasing collaboration between healthcare and technology providers. AI's integration into cancer diagnostics is enhancing detection accuracy, optimizing workflows, and enabling precision oncology at an unprecedented scale.
As strategic initiatives and regulatory support continue to grow, AI is set to redefine the landscape of cancer care-making diagnostics faster, smarter, and more patient-centric by 2032.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=artificial-intelligence-ai-in-cancer-diagnostics-market-poised-for-robust-growth-reaching-usd-243-billion-by-2032-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Artificial Intelligence (AI) in Cancer Diagnostics Market Poised for Robust Growth, Reaching USD 2.43 Billion by 2032 | DelveInsight here
News-ID: 4212752 • Views: …
More Releases from ABNewswire
The Silver Clover & Co. Launches Revolutionary Jewelry Gift Experience Combining …
Emerging jewelry retailer The Silver Clover & Co. debuts an innovative approach to meaningful gift-giving by pairing every piece of jewelry with beautifully designed message cards and luxury presentation packaging. The company's unique concept transforms traditional jewelry purchases into memorable storytelling experiences, featuring customizable options and elegant LED-lit mahogany-style luxury boxes.
The Silver Clover & Co. has officially launched with a mission to revolutionize how people experience jewelry gift-giving. The Silver…
Jonesing4 JAVA Launches Premium Direct-Trade Coffee Service with Exotic Origins …
New specialty coffee roaster Jonesing4 JAVA debuts with a commitment to freshness and direct farmer partnerships across three continents. The company's roast-to-order model guarantees customers receive the freshest possible coffee while supporting sustainable farming practices in renowned growing regions.
Jonesing4 JAVA, a newly launched specialty coffee company, is transforming how consumers experience premium coffee through its innovative direct-trade partnerships and roast-to-order business model. The company has established relationships with farmers and…
Drawers Co. Revolutionizes Children's Underwear Market with Color-Coded Laundry …
Drawers Co., an innovative children's underwear and socks brand, has introduced a groundbreaking color-coded system that simplifies laundry sorting for parents while delivering comfort-focused, tag-free designs that kids love. The company's unique approach addresses two major pain points in children's clothing: laundry management and comfort.
Drawers Co. is transforming the children's underwear market through an innovative approach that addresses both parent convenience and child comfort with their revolutionary color-coded laundry system…
Lazy Genius Official Disrupts Beauty Industry with Ethics-First Approach and Leg …
Emerging beauty brand Lazy Genius Official combines cruelty-free cosmetics with unprecedented social impact by directing proceeds toward launching a legal insurance company for underserved cases. The company's vegan, made-to-order products offer conscious consumers a way to support both personal wellness and systemic change.
Lazy Genius Official was born after founder Anni Yang experienced workplace discrimination when her manager wrote her up after she disclosed that she was on her period.
That experience…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
